Skip to main content
Figure 11 | BMC Cancer

Figure 11

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Figure 11

Effects of dasatinib and/or Eto on the proportion of ALDH1-positive cells in MDA-MB-157 cells. The cells were treated with 0.1 μM Eto and/or 0.1 μM dasatinib for two days, and ALDH1-positive cells were measured by the immunocytochemical analysis as described in the Materials and Methods. Dasatinib alone and dasatinib with Eto significantly decreased the proportion of ALDH1-positive cells in MDA-MB-157 cells. **P < 0.01.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us